Recontrast and Renal Outcomes in Patients With Pre-Existing Renal Dysfunction

NCT07713524 | Completed

• 1 other identifier: N-20-2024
• Study Type: observational
• Target: 112
• Locations: 1 country
• Sites: 1

Brief Summary

Aim of study: The renal impact of repeated iodinated contrast exposure in critically ill patients with pre-existing renal impairment Methods: A prospective observational cohort study included 112 critically ill patients admitted to the intensive care units of Cairo University hospitals with baseline estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73 m² who underwent one or two intravascular iodinated contrast administrations. Hemodynamically unstable patients were excluded. Patients were systematically followed to evaluate both short- and long-term renal outcomes. Serum creatinine, eGFR, urine output, contrast-associated acute kidney injury (CA-AKI), chronic kidney disease (CKD) progression and dialysis requirement were assessed after each exposure and during 6 months follow-up. Logistic regression analysis was performed.

Conditions

Kidney Diseases

Outcome Measures

Primary Outcomes (1)

• Contrast-associated AKI [ Acute Kidney Injury ] defined by KDIGO [Kidney Disease Improving Global Outcomes] criteria

  3 months

Secondary Outcomes (1)

• Progression of CKD stage

  6 months

Other Outcomes (1)

• Need for renal replacement therapy

  6 months

Study Arms (2)

a single-exposure group

patients who underwent a single contrast exposure with impaired kidney function.

a repeated-exposure group

Patients who received two contrast administrations with impaired kidney function.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pre-existing renal impairment defined by KDIGO criteria who subjected to contrast exposure once or more

You may qualify if:

• Adults aged 18 years or older with baseline eGFR \<90 mL/min/1.73 m² who underwent at least one intravascular iodinated contrast study

You may not qualify if:

• Kidney transplant within the preceding 6 months
• Ongoing renal replacement therapy
• Hemodynamic shock
• Severe sepsis
• Recent nephrotoxic drug exposure
• Incomplete laboratory data
• Prior contrast allergy.

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Faculty of medicine

Cairo, KasrAlainy, 11562, Egypt

Location

MeSH Terms

Conditions

Kidney Diseases

Condition Hierarchy (Ancestors)

Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professor

Study Record Dates

• First Submitted: July 14, 2026
• First Posted: July 20, 2026
• Study Start: March 1, 2024
• Primary Completion: November 30, 2025
• Study Completion: February 28, 2026
• Last Updated: July 21, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share

Locations

EG (1)